Dewormer
Fluralaner is an isoxazoline insecticide and acaricide. It antagonizes GABA receptors and glutamate-gated chloride channels, blocking chloride ion permeation across the postsynaptic membrane. This disrupts transmembrane signal transmission in the nervous system and leads to the death of parasites. No cross-resistance has been found between fluralaner and dieldrin.
(1) Fluralaner 25 mg + Moxidectin 0.06 mg + Pyrantel Pamoate 12.5 mg
(2) Fluralaner 50 mg + Moxidectin 0.12 mg + Pyrantel Pamoate 25 mg
(3) Fluralaner 100 mg + Moxidectin 0.24 mg + Pyrantel Pamoate 50 mg
(4) Fluralaner 200 mg + Moxidectin 0.48 mg + Pyrantel Pamoate 100 mg
(5) Fluralaner 400 mg + Moxidectin 0.96 mg + Pyrantel Pamoate 200 mg
Fluralaner is an isoxazoline insecticide and acaricide. It antagonizes GABA receptors and glutamate-gated chloride channels, blocking chloride ion permeation across the postsynaptic membrane. This disrupts transmembrane signal transmission in the nervous system and leads to the death of parasites. No cross-resistance has been found between fluralaner and dieldrin.
As a systemic antiparasitic agent, fluralaner provides 12-week persistent efficacy against fleas and ticks on dogs. It acts rapidly against adult fleas including Ctenocephalides felis and Ctenocephalides canis, inhibits flea oviposition and thereby breaks the flea life cycle. It is also effective against all developmental stages (larvae, nymphs and adults) of ticks such as Ixodes ricinus, Ixodes hexagonus, Ixodes scapularis, Ixodes holocyclus, Dermacentor reticulatus, Dermacentor variabilis and Rhipicephalus sanguineus.
Moxidectin is a second-generation macrolide milbemycin compound. It primarily interferes with signal transmission at neuromuscular junctions via glutamate-gated chloride channels (partially via GABA-gated chloride channels), resulting in sustained opening of postsynaptic channels, chloride ion influx, and subsequent flaccid paralysis and death of parasites. Moxidectin is effective against Toxocara canis, Ancylostoma caninum and prevents canine heartworm disease.
Pyrantel pamoate acts as a nicotinic acetylcholine receptor (nAChR) agonist. It selectively binds to nematode nicotinic receptors (no binding to muscarinic receptors), triggering cation influx, depolarization of nematode muscle cells, increased excitability, and eventual spastic paralysis and death of parasites. It is efficacious against adult and immature Toxocara canis, Toxascaris leonina, Ancylostoma caninum (L4 larvae, immature adults and adults) and adult Uncinaria stenocephala.
Fluralaner is readily absorbed after oral administration, reaching peak plasma concentration within 24 hours; food enhances its absorption. It distributes systemically with the highest concentration in adipose tissue, followed by liver, kidneys and muscles. Fluralaner is barely metabolized in dogs, with a plasma elimination half-life of approximately 12 days, maintaining effective plasma concentrations throughout the dosing interval. Individual variations in peak concentration and elimination half-life exist. Approximately 90% of fluralaner is excreted unchanged in faeces, and a small portion via urine.
Combined use of fluralaner, moxidectin and pyrantel pamoate does not alter their respective pharmacokinetic profiles. Food intake has no impact on the absorption of this product.
For the treatment of tick infestations (Ixodes hexagonus, Ixodes ricinus, Rhipicephalus sanguineus, Dermacentor reticulatus) in dogs; For the treatment of flea infestations (Ctenocephalides felis, Ctenocephalides canis) in dogs; For the treatment of immature adults (L5) and adult Toxocara canis, and adult Toxascaris leonina infections; For the treatment of L4 larvae, immature adults (L5) and adult Ancylostoma caninum, as well as adult Uncinaria stenocephala infections; For the prevention of canine heartworm dise
For oral use. Administer once monthly at the dose specified below:
|
Body |
Specification |
Quantity |
|
1.25～2.5 |
1 |
1 tablet |
|
2.5～5 |
2 |
1 tablet |
|
5～10 |
3 |
1 tablet |
|
10～20 |
4 |
1 tablet |
|
20～40 |
5 |
1 tablet |
|
>40 |
Combine appropriate specifications |
|
1. Mild and transient gastrointestinal reactions including diarrhoea, vomiting, inappetence and salivation were observed in a small number of dogs (1.6%).
2. In 8–9 week-old puppies weighing 2.0–3.6 kg, administration of 5 times the maximum recommended dose of fluralaner once every 8 weeks for 3 consecutive times caused no adverse reactions.
3. Administration of 3 times the maximum recommended dose of fluralaner in Beagle dogs showed no adverse effects on reproductive performance or offspring viability.
4. Collie dogs with MDR1 gene deletion (MDR1-/-) exhibited good tolerance after receiving 3 times the maximum recommended dose of fluralaner, with no treatment-related clinical signs observed.
1. Do not administer to dogs with known hypersensitivity to this product.
2. Due to limited safety data, use in puppies younger than 8 weeks old and/or weighing less than 1.25 kg only after veterinary risk assessment.
3. Dogs with multidrug resistance protein 1 deficiency (MDR1-/-) tolerate a single dose of 3 times the recommended dosage well. A single dose of 5 times the recommended dosage may cause transient ataxia and/or muscle tremors.
4. Safety for pregnant, lactating and breeding dogs has not been established. Use in these animals is not recommended.
5. Examine dogs for heartworm infection prior to administration. Dogs with confirmed heartworm infection shall receive adulticide treatment first. This product is not effective against adult heartworms; accidental use in heartworm-positive dogs poses no safety risks.
6. Frequent and repeated use may lead to parasite drug resistance. Use this product based on individual animal conditions, local epidemiological data and parasite susceptibility to reduce the development of drug resistance.
7. Wash hands thoroughly after handling the product. Ingestion by humans may cause adverse reactions including transient neurological excitation; seek immediate medical attention if accidental ingestion occurs.
8. Keep out of reach of children.
9. Dispose of residual drug and waste in accordance with relevant regulations.
Not applicable.
